Long-term oral acyclovir therapy

Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts

A. L. Simon, D. Pavan-Langston, Penny Asbell

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy of long-term oral acyclovir therapy in reducing recurrences of dendritic or geographic herpes simplex keratitis (HSK). Methods: Thirteen patients with a history of frequently recurring HSK were followed before (mean, 27 months) and during long-term systemic acyclovir, and eight were followed after the acyclovir was discontinued. Results: Treatment ranged from 8.5 to 62 months (mean, 34 months). During treatment, the number of recurrences per month decreased from 0.15 to 0.03, and the average duration of relapses decreased from 12.6 to 7.8 days. Recurrences correlated with daily doses of oral acyclovir of 800 mg or less, intraocular surgery within 6 weeks of initiating treatment, and discontinuation of therapy against medical advice. Conclusion: The results of this small study appear to demonstrate the efficacy of long-term oral acyclovir in prophylaxis of recurrent epithelial herpes simplex infection: therapeutic doses of oral acyclovir reduce both the rate and duration of recurrences of infectious herpetic keratitis. A multicenter, double-masked, placebo-controlled study is indicated.

Original languageEnglish (US)
Pages (from-to)1399-1405
Number of pages7
JournalOphthalmology
Volume103
Issue number9
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Herpetic Keratitis
Acyclovir
Transplants
Recurrence
Therapeutics
Herpes Simplex
Placebos
Infection

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Long-term oral acyclovir therapy : Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts. / Simon, A. L.; Pavan-Langston, D.; Asbell, Penny.

In: Ophthalmology, Vol. 103, No. 9, 01.01.1996, p. 1399-1405.

Research output: Contribution to journalArticle

@article{1c9f3fdb8f214a21a00c1251819c7f54,
title = "Long-term oral acyclovir therapy: Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts",
abstract = "Purpose: To evaluate the efficacy of long-term oral acyclovir therapy in reducing recurrences of dendritic or geographic herpes simplex keratitis (HSK). Methods: Thirteen patients with a history of frequently recurring HSK were followed before (mean, 27 months) and during long-term systemic acyclovir, and eight were followed after the acyclovir was discontinued. Results: Treatment ranged from 8.5 to 62 months (mean, 34 months). During treatment, the number of recurrences per month decreased from 0.15 to 0.03, and the average duration of relapses decreased from 12.6 to 7.8 days. Recurrences correlated with daily doses of oral acyclovir of 800 mg or less, intraocular surgery within 6 weeks of initiating treatment, and discontinuation of therapy against medical advice. Conclusion: The results of this small study appear to demonstrate the efficacy of long-term oral acyclovir in prophylaxis of recurrent epithelial herpes simplex infection: therapeutic doses of oral acyclovir reduce both the rate and duration of recurrences of infectious herpetic keratitis. A multicenter, double-masked, placebo-controlled study is indicated.",
author = "Simon, {A. L.} and D. Pavan-Langston and Penny Asbell",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0161-6420(96)30492-2",
language = "English (US)",
volume = "103",
pages = "1399--1405",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Long-term oral acyclovir therapy

T2 - Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts

AU - Simon, A. L.

AU - Pavan-Langston, D.

AU - Asbell, Penny

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: To evaluate the efficacy of long-term oral acyclovir therapy in reducing recurrences of dendritic or geographic herpes simplex keratitis (HSK). Methods: Thirteen patients with a history of frequently recurring HSK were followed before (mean, 27 months) and during long-term systemic acyclovir, and eight were followed after the acyclovir was discontinued. Results: Treatment ranged from 8.5 to 62 months (mean, 34 months). During treatment, the number of recurrences per month decreased from 0.15 to 0.03, and the average duration of relapses decreased from 12.6 to 7.8 days. Recurrences correlated with daily doses of oral acyclovir of 800 mg or less, intraocular surgery within 6 weeks of initiating treatment, and discontinuation of therapy against medical advice. Conclusion: The results of this small study appear to demonstrate the efficacy of long-term oral acyclovir in prophylaxis of recurrent epithelial herpes simplex infection: therapeutic doses of oral acyclovir reduce both the rate and duration of recurrences of infectious herpetic keratitis. A multicenter, double-masked, placebo-controlled study is indicated.

AB - Purpose: To evaluate the efficacy of long-term oral acyclovir therapy in reducing recurrences of dendritic or geographic herpes simplex keratitis (HSK). Methods: Thirteen patients with a history of frequently recurring HSK were followed before (mean, 27 months) and during long-term systemic acyclovir, and eight were followed after the acyclovir was discontinued. Results: Treatment ranged from 8.5 to 62 months (mean, 34 months). During treatment, the number of recurrences per month decreased from 0.15 to 0.03, and the average duration of relapses decreased from 12.6 to 7.8 days. Recurrences correlated with daily doses of oral acyclovir of 800 mg or less, intraocular surgery within 6 weeks of initiating treatment, and discontinuation of therapy against medical advice. Conclusion: The results of this small study appear to demonstrate the efficacy of long-term oral acyclovir in prophylaxis of recurrent epithelial herpes simplex infection: therapeutic doses of oral acyclovir reduce both the rate and duration of recurrences of infectious herpetic keratitis. A multicenter, double-masked, placebo-controlled study is indicated.

UR - http://www.scopus.com/inward/record.url?scp=0029806761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029806761&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(96)30492-2

DO - 10.1016/S0161-6420(96)30492-2

M3 - Article

VL - 103

SP - 1399

EP - 1405

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -